FR-181074
FR-181074 is a selective and orally active PDE V inhibitor. FR-181074 can specifically block PDE V to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in order to relax smooth muscle. FR-181074 can be used for the researches of cardiovascular disease and endocrinology, such as hypertension and erectile dysfunction[1].
Product Specifications
CAS Number
[184147-65-7]
UNSPSC
12352005
Target
Phosphodiesterase (PDE)
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cardiovascular Disease; Metabolic Disease
Smiles
O=C(C1=CC(N(CC2=C(Cl)C=CC=C2)C(CCC)=C3C(C(C)C)=O)=C3C=C1)N
Molecular Formula
C23H25ClN2O2
Molecular Weight
396.91
References & Citations
[1]Jinal PANDYA, et al. Liquid oral formulations for pde v inhibitors. WO 2019/130052 Al. 2019-07-04
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PDE5
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Protein Gene Product 9.5 (PGP9.5, UchL1, Ubiquitin C-terminal Hydrolase, PARK5)
Protein Gene Product 9.5 (PGP9.5, UchL1, Ubiquitin C-terminal Hydrolase, PARK5)
PI3KC3, NT (PIK3C3, VPS34, Phosphatidylinositol 3-kinase catalytic subunit type 3, Phosphatidylinositol 3-kinase p100 subunit, Phosphoinositide-3-kinase class 3, hVps34) (MaxLight 405)
PI3KC3, NT (PIK3C3, VPS34, Phosphatidylinositol 3-kinase catalytic subunit type 3, Phosphatidylinositol 3-kinase p100 subunit, Phosphoinositide-3-kinase class 3, hVps34) (MaxLight 405)